Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum spp. infantis YLGB-1496
- Development stage
- Preclinical
- Lead developer
- Yili Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum spp. infantis YLGB-1496 is a proprietary probiotic strain isolated from human breast milk. [2, 3] It is being developed to modulate the gut microbiome and immune system, particularly in children. [1, 3] Clinical studies have shown that it can reduce the incidence of respiratory and gastrointestinal illnesses, such as upper respiratory tract infections (URTIs), bronchopneumonia, diarrhea, and eczema in children. [1, 3, 7] The mechanism of action involves modulating the gut microbiome, reducing pro-inflammatory cytokines like IL-1β and IFN-γ, and increasing the production of beneficial short-chain fatty acids (SCFAs) and immunoglobulins like IgA. [1, 3, 7] It is administered orally as a powder. [3] The strain is registered with the China Center for Type Culture Collection (CCTCC No. M2011122). [3]
- Other names
- Bifidobacterium infantis YLGB-1496婴儿双歧杆菌YLGB-1496CCTCC M2011122
Beyond the preview
Go deeper on bifidobacterium longum spp. infantis YLGB-1496.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum spp. infantis YLGB-1496.